Is there a relation between myalgia and central nervous system symptoms in patients receiving Raltegravir? Results from the Scolta Project.

Introduction: Raltegravir, the first HIV integrase inhibitor available in clinical practice for the treatment of HIV-infection, has shown a good safety profile. However, muscle alterations ranging from asymptomatic creatine phosphokinase (CPK) increases to rhabdomyolysis and central nervous system symptoms (CNS) have been reported in literature. No study to date has evaluated the possible interactions between muscle and CNS adverse events.